Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis
Authors' conclusion
In this post hoc analysis, tirzepatide was associated with improvements in biomarkers of metabolic/adiposity/hepatic stress and endothelial dysfunction, as well as selected biomarkers of inflammation and hemostasis/thrombosis.
Study context
- Population
- People with obesity or overweight in SURMOUNT-1 who completed treatmentafter low sample volumes excluded
- Participants
- 392 people
- Comparison
- Tirzepatide 5, 10 or 15 mg vs placebo
- Primary endpoint
- Change in each log-transformed CV risk biomarker (% change in geometric means vs placebo)
- Follow-up
- 72 weeks
Methodological detailsplacebo-controlled, 100 randomly selected participants per group
- Placebo-controlled
- 100 randomly selected participants per group
Primary result
As reported in the abstract
% change in biomarker geometric means vs placebo (5, 10, 15 mg) · Week 72
- hs-CRP (5, 10, 15 mg)
- −36.9%, −46.9%, −54.6%
- Interleukin-6
- −25.4%, −27.8%, −30.2%
- Leukocytes
- NS, −8.6%, −10.0%
- HOMA-IR
- −26.4%, −35.5%, −39.1%
- Leptin
- −44.4%, −59.3%, −61.4%
- Gamma-glutamyl transferase
- −18.6%, −21.6%, −32.7%
- Fibroblast growth factor-21
- −27.4%, −27.6%, −39.9%
- Adiponectin
- 21.1%, 35.1%, 47.7%
- Free fatty acids
- NS, NS, −17.1%
- Soluble ICAM-1
- NS, −9.7%, −11.1%
- E-selectin
- −12.6%, −20.0%, −26.4%
- PAI-1:Ag
- −41.4%, −35.6%, −44.3%
- Platelets
- NS, NS, −6.0%
Original publication
Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis. J Am Coll Cardiol. Published 3 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →